Waldenstrom's Macroglobulinemia — Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)
Citation(s)
Phase II Study of Combination Bortezomib (Velcade PS-341) and Rituximab in Patients With Previously Untreated and Relapsed/Refractory Waldenstrom's Macroglobulinemia